Parissenti, A. M., Pritzker, L. B., Dahle, M. A., Gythfeldt, H. v. d. L., Masilamani, T., Theriault, G., . . . Engebraaten, O. (2025). High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy. Breast Cancer Research, 27(1), 1-13.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Parissenti, Amadeo M., et al. "High Mid-treatment Tumour RNA Disruption in Patients with HER2-negative Breast Cancer Is Associated with Improved Disease-free Survival After Neoadjuvant Chemotherapy."
Breast Cancer Research 27, no. 1 (2025): 1-13.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Parissenti, Amadeo M., et al. "High Mid-treatment Tumour RNA Disruption in Patients with HER2-negative Breast Cancer Is Associated with Improved Disease-free Survival After Neoadjuvant Chemotherapy."
Breast Cancer Research, vol. 27, no. 1, 2025, pp. 1-13.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.